new results just released by @Novavax for their UK and South African SARS-CoV-2 vaccine trials ir.novavax.com/news-releases/…
NVX-CoV2373 contains a recombinant Spike glycoprotein maintained in prefusion conformation with 2 proline substitutions nature.com/articles/s4146… 1/n
NVX-CoV2373 contains a recombinant Spike glycoprotein maintained in prefusion conformation with 2 proline substitutions nature.com/articles/s4146… 1/n
the UK arm enrolled more than 15,000 participants aged 18-84 with a primary endpoint of PCR confirmed symptomatic COVID-19
62 cases were observed overall, 56 in the placebo group and 6 in the NVX-CoV2373 group, giving an efficacy of 89.3% 2/n
62 cases were observed overall, 56 in the placebo group and 6 in the NVX-CoV2373 group, giving an efficacy of 89.3% 2/n
the researchers also carried out a post-hoc analysis looking at efficacy for particular strains
they estimated an efficacy of 95.6% against the original COVID-19 strain and 85.6% against the UK variant strain B.1.1.7 3/n
they estimated an efficacy of 95.6% against the original COVID-19 strain and 85.6% against the UK variant strain B.1.1.7 3/n
the South African arm was smaller, enrolling 4,400 participants
results are reported for HIV -ve participants
29 participants who received the placebo developed infection, and 15 of those that received NVX-CoV2373, giving an efficacy of 60% 4/n
results are reported for HIV -ve participants
29 participants who received the placebo developed infection, and 15 of those that received NVX-CoV2373, giving an efficacy of 60% 4/n
of the 44 participants that received a diagnosis of PCR confirmed COVID-19, 27 had samples available, and 25 of these were the 501Y.V2 variant
suggestive of reduced efficacy of vaccine against 501Y.V2 variant, consistent with laboratory studies e.g. medrxiv.org/content/10.110… 5/n
suggestive of reduced efficacy of vaccine against 501Y.V2 variant, consistent with laboratory studies e.g. medrxiv.org/content/10.110… 5/n
and also with recent release from @moderna_tx investors.modernatx.com/news-releases/…
which shows a six-fold reduction in neutralising titres for B.1.351 (501Y.V2) variant relative to prior variants
although in this study titres were predicted to still be protective @BarneyGrahamMD 6/n
which shows a six-fold reduction in neutralising titres for B.1.351 (501Y.V2) variant relative to prior variants
although in this study titres were predicted to still be protective @BarneyGrahamMD 6/n
this is the first real world, clinical trial data looking at the effectiveness of a Spike glycoprotein based vaccine against the 501Y.V2 variant 7/n
some key questions:
1. How will the immune response (B and T cell) to the @Novavax Spike sequence compare to that used by @pfizer, @moderna_tx or @AstraZeneca as regards new variants? @jbloom_lab 8/n
1. How will the immune response (B and T cell) to the @Novavax Spike sequence compare to that used by @pfizer, @moderna_tx or @AstraZeneca as regards new variants? @jbloom_lab 8/n
2. What will data from the @JNJGlobalHealth trial, also from SA (due to come out next week) show? @virusmonologues 9/n
as ever, a lot more new, non-peer reviewed data in a rapidly evolving field
but enough to give us food for thought
and remind us of key steps we need to take:
-interrupt transmission & bring down case numbers
-facilitate immunisation
to tackle this GLOBAL crisis @JeremyFarrar
but enough to give us food for thought
and remind us of key steps we need to take:
-interrupt transmission & bring down case numbers
-facilitate immunisation
to tackle this GLOBAL crisis @JeremyFarrar
• • •
Missing some Tweet in this thread? You can try to
force a refresh
